SpringWorks Therapeutics Inc Ordinary Shares SWTX
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if SWTX is a good fit for your portfolio.
News
-
SpringWorks Therapeutics to Report Second Quarter 2024 Financial Results on Wednesday, August 7, 2024
-
Kuehn Law Encourages Investors of SpringWorks, Therapeutics Inc. to Contact Law Firm
-
SpringWorks Therapeutics Completes Submission of New Drug Application to the FDA for Mirdametinib for the Treatment of Children and Adults with NF1-PN
-
SpringWorks Therapeutics to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference
-
SpringWorks Therapeutics Announces Data to be Presented at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
-
SpringWorks Therapeutics to Participate in the BofA Securities 2024 Health Care Conference
-
SpringWorks Therapeutics Reports First Quarter 2024 Financial Results and Highlights Recent Business Updates
-
SpringWorks stock on track for record gain after FDA approves first treatment for rare type of aggressive tumors
Trading Information
- Previous Close Price
- $36.87
- Day Range
- $36.73–38.67
- 52-Week Range
- $18.00–53.92
- Bid/Ask
- $36.99 / $39.92
- Market Cap
- $2.82 Bil
- Volume/Avg
- 515,590 / 821,630
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 94.89
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
SpringWorks Therapeutics Inc is a clinical stage biopharmaceutical company applying a precision medicine approach to acquiring, developing and commercializing life-changing medicines for underserved patient populations suffering from devastating rare diseases and cancer. The company has a differentiated portfolio of small molecule targeted oncology product candidates and is advancing two potentially registrational clinical trials in rare tumor types, as well as several other programs addressing highly prevalent, genetically defined cancers.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Growth
- Total Number of Employees
- 305
- Website
- https://www.springworkstx.com
Comparables
Valuation
|
Metric
|
SWTX
|
TYRA
|
VRDN
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | 4.96 | 2.70 | 2.78 |
Price/Sales | 94.89 | — | 2,861.56 |
Price/Cash Flow | — | — | — |
Price/Earnings
SWTX
TYRA
VRDN
Financial Strength
|
Metric
|
SWTX
|
TYRA
|
VRDN
|
|---|---|---|---|
Quick Ratio | 6.56 | 43.88 | 23.47 |
Current Ratio | 6.85 | 44.83 | 23.99 |
Interest Coverage | — | — | −104.84 |
Quick Ratio
SWTX
TYRA
VRDN
Profitability
|
Metric
|
SWTX
|
TYRA
|
VRDN
|
|---|---|---|---|
Return on Assets (Normalized) | −40.43% | −21.92% | −35.08% |
Return on Equity (Normalized) | −46.62% | −23.10% | −65.95% |
Return on Invested Capital (Normalized) | −50.77% | −27.33% | −42.29% |
Return on Assets
SWTX
TYRA
VRDN
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Novo Nordisk A/S ADR
NVO
| Nmqbxqrrg | Blslq | $565.6 Bil | |||
| Vertex Pharmaceuticals Inc
VRTX
| Jcswhkq | Kfknc | $127.8 Bil | |||
| Regeneron Pharmaceuticals Inc
REGN
| Pfzfcqydg | Wspflz | $118.7 Bil | |||
| Moderna Inc
MRNA
| Hnftsybj | Tykj | $46.8 Bil | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Rvmchcb | Yhxdkdw | $29.7 Bil | |||
| argenx SE ADR
ARGX
| Svyfshr | Mbpb | $29.3 Bil | |||
| BioNTech SE ADR
BNTX
| Yyxfrzq | Mtp | $20.7 Bil | |||
| Biomarin Pharmaceutical Inc
BMRN
| Gkpynjj | Blxkgpp | $16.1 Bil | |||
| United Therapeutics Corp
UTHR
| Rnvdthf | Nmwns | $15.0 Bil | |||
| Incyte Corp
INCY
| Xlkxdshz | Qlnhzwv | $13.5 Bil |